Skip to main content
Equibles
ROIV logo

ROIV · Roivant Sciences Ltd. · Metrics

Track ROIV — free

Use ROIV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ROIV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.37 +0.67 (+1.92%)
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$25.06B
Shares
722.32M
Volume · Oct 20 676.17K Avg daily vol (3M) 7.1M

ROIV metrics

79 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$34.70
Market cap
$25.06B

Price action

20 metrics
Price change (1W)
+0.3%
Price change (30D)
-11.0%
Price change (3M)
+1.9%
Price change (6M)
+19.3%
Price change (YTD)
+59.9%
Price change (1Y)
+101.0%
Trailing year
Price change (5Y)
+453.4%
52-week high
$41.81
52-week low
$17.74
Change from 52-week high
-17.0%
Change from 52-week low
+95.6%
Annualized volatility
46.9%
Annualized volatility (3M)
51.0%
Beta
1.1
RSI (14D)
45.0
Price vs SMA 50
-5.2%
Price vs SMA 200
+12.5%
Avg volume (3M)
7.10M
Relative volume
0.9
Average dollar volume
$260.06M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
722.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2,705.4×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
3,215.5×
reciprocal yield 0.0%
P / book
5.7
reciprocal yield 17.5%
FCF yield
—
TTM · current market cap
Buyback yield
2.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
423.3×
reciprocal yield 0.2%
EV / revenue historical average (5Y)
303.6×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
0.6×
reciprocal yield 172.4%
EV / EBIT historical average (5Y)
0.6×
reciprocal yield 172.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
2.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-08

Profitability

9 metrics
Gross margin
—
Operating margin
-7,914.8%
Trailing 12 months
Net margin
-2,837.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$596.14M
Net income (TTM)
−$213.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.47
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.87
EBITDA per diluted share (TTM)
$-0.86
Net income per diluted share (TTM)
$-0.32
Operating cash flow per diluted share (TTM)
$-1.16
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.04
Stock compensation per diluted share (TTM)
$0.49
Book value per share
$6.28

Growth

11 metrics
Revenue growth YoY
-33.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.53M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.0%
Year over year · more shares
Revenue CAGR (3Y)
-36.0%
Revenue CAGR (5Y)
-19.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-5.1%
Return on assets
-4.0%
Debt / equity
0.0
Current ratio
16.7
EBITDA (TTM)
−$593.29M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.84B
Latest balance sheet
Cash & equivalents
$1.25B
Total assets
$5.31B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$816.47M
Capital expenditures (TTM)
$4.59M
R&D (TTM)
$730.91M
SG&A (TTM)
$679.77M
Stock compensation (TTM)
$347.33M
R&D / revenue
9,704.0%
Stock compensation / revenue
4,611.4%

Ownership (13F)

3 metrics
13F filers
502
13F filer change QoQ
+52
Institutional ownership
79.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.5%

Short interest

3 metrics
Short interest
5.4%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$59.83M
Insider-sentiment score
22 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1635088 CUSIP G76279101 13F (30d) 61 filings 58 filers Visit website Investor relations